Cargando…

Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis

Immunosuppressive drugs are routinely used to treat myasthenia gravis (MG). However, current recommendations provide limited evidence to support treatment options, leading to considerable variation in practice among healthcare specialists. Hence, we present a protocol for a systematic review and net...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peng, Zhang, Ying, Chang, Tianying, Jiang, Li, Lv, Zhiguo, Zhang, Yibin, Xu, Hanying, Zhang, Dongmei, Lan, Tianye, Cui, Yingzi, Hua, Zhen, Gao, Chengfei, Lu, Jing, Huang, Qingxia, Tian, Jinhui, Ma, Jihui, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771229/
https://www.ncbi.nlm.nih.gov/pubmed/36550882
http://dx.doi.org/10.1097/MD.0000000000031454
_version_ 1784854776529289216
author Xu, Peng
Zhang, Ying
Chang, Tianying
Jiang, Li
Lv, Zhiguo
Zhang, Yibin
Xu, Hanying
Zhang, Dongmei
Lan, Tianye
Cui, Yingzi
Hua, Zhen
Gao, Chengfei
Lu, Jing
Huang, Qingxia
Tian, Jinhui
Ma, Jihui
Wang, Jian
author_facet Xu, Peng
Zhang, Ying
Chang, Tianying
Jiang, Li
Lv, Zhiguo
Zhang, Yibin
Xu, Hanying
Zhang, Dongmei
Lan, Tianye
Cui, Yingzi
Hua, Zhen
Gao, Chengfei
Lu, Jing
Huang, Qingxia
Tian, Jinhui
Ma, Jihui
Wang, Jian
author_sort Xu, Peng
collection PubMed
description Immunosuppressive drugs are routinely used to treat myasthenia gravis (MG). However, current recommendations provide limited evidence to support treatment options, leading to considerable variation in practice among healthcare specialists. Hence, we present a protocol for a systematic review and network meta-analysis (NMA) to update the evidence by comparing the efficacy and acceptability of oral immunosuppressive drugs for the treatment of MG. METHODS: We will conduct a systematic review and NMA of all randomized controlled trials evaluating the following oral immunosuppressive drugs for the treatment of MG. Published studies will be searched using the following databases from inception to November 23, 2021: CENTRAL, the CINAHL, MEDLINE, Embase, PsycINFO, Web of Science, and 3 Chinese databases (Chinese Biomedical Literatures Database, CNKI, and Wan Fang database). Assessment of study eligibility and data extraction will be conducted independently by 2 reviewers. The main outcome will be a quantitative MG scoring system. We will conduct Bayesian NMA to synthesize all evidence for each outcome and obtain a comprehensive ranking of all treatments. The quality of the evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations framework. RESULTS: The objective of this study was to assess the relative clinical efficacy and acceptability of first-line immunosuppressants for the treatment of MG, using a systematic review and NMA approach. CONCLUSION: In the absence of head-to-head trials comparing therapies, evidence from this NMA of available clinical trials will inform clinicians, patients, and families the risk-benefit profiles of different treatment options.
format Online
Article
Text
id pubmed-9771229
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97712292022-12-22 Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis Xu, Peng Zhang, Ying Chang, Tianying Jiang, Li Lv, Zhiguo Zhang, Yibin Xu, Hanying Zhang, Dongmei Lan, Tianye Cui, Yingzi Hua, Zhen Gao, Chengfei Lu, Jing Huang, Qingxia Tian, Jinhui Ma, Jihui Wang, Jian Medicine (Baltimore) 5300 Immunosuppressive drugs are routinely used to treat myasthenia gravis (MG). However, current recommendations provide limited evidence to support treatment options, leading to considerable variation in practice among healthcare specialists. Hence, we present a protocol for a systematic review and network meta-analysis (NMA) to update the evidence by comparing the efficacy and acceptability of oral immunosuppressive drugs for the treatment of MG. METHODS: We will conduct a systematic review and NMA of all randomized controlled trials evaluating the following oral immunosuppressive drugs for the treatment of MG. Published studies will be searched using the following databases from inception to November 23, 2021: CENTRAL, the CINAHL, MEDLINE, Embase, PsycINFO, Web of Science, and 3 Chinese databases (Chinese Biomedical Literatures Database, CNKI, and Wan Fang database). Assessment of study eligibility and data extraction will be conducted independently by 2 reviewers. The main outcome will be a quantitative MG scoring system. We will conduct Bayesian NMA to synthesize all evidence for each outcome and obtain a comprehensive ranking of all treatments. The quality of the evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations framework. RESULTS: The objective of this study was to assess the relative clinical efficacy and acceptability of first-line immunosuppressants for the treatment of MG, using a systematic review and NMA approach. CONCLUSION: In the absence of head-to-head trials comparing therapies, evidence from this NMA of available clinical trials will inform clinicians, patients, and families the risk-benefit profiles of different treatment options. Lippincott Williams & Wilkins 2022-12-16 /pmc/articles/PMC9771229/ /pubmed/36550882 http://dx.doi.org/10.1097/MD.0000000000031454 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5300
Xu, Peng
Zhang, Ying
Chang, Tianying
Jiang, Li
Lv, Zhiguo
Zhang, Yibin
Xu, Hanying
Zhang, Dongmei
Lan, Tianye
Cui, Yingzi
Hua, Zhen
Gao, Chengfei
Lu, Jing
Huang, Qingxia
Tian, Jinhui
Ma, Jihui
Wang, Jian
Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis
title Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis
title_full Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis
title_fullStr Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis
title_full_unstemmed Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis
title_short Comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: A protocol for systematic review and network meta-analysis
title_sort comparative the efficacy and acceptability of immunosuppressive agents for myasthenia gravis: a protocol for systematic review and network meta-analysis
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771229/
https://www.ncbi.nlm.nih.gov/pubmed/36550882
http://dx.doi.org/10.1097/MD.0000000000031454
work_keys_str_mv AT xupeng comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT zhangying comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT changtianying comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT jiangli comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT lvzhiguo comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT zhangyibin comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT xuhanying comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT zhangdongmei comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT lantianye comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT cuiyingzi comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT huazhen comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT gaochengfei comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT lujing comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT huangqingxia comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT tianjinhui comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT majihui comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis
AT wangjian comparativetheefficacyandacceptabilityofimmunosuppressiveagentsformyastheniagravisaprotocolforsystematicreviewandnetworkmetaanalysis